A Canadian company says it is on track to produce 50 million doses of its COVID-19 vaccine this year, which if approved, could give the country’s vaccine supply a much-needed boost to fight the coronavirus pandemic.

Calgary-based vaccine maker, Providence Therapeutics, is still in the early stages of clinical trials for its mRNA vaccine candidate, and Manitoba is the only province that has announced a deal with them.

“Providence can have millions of doses of messenger-RNA vaccine by this fall. We’re on that path now,” Ken Hughes, chair of the board at Providence Therapeutics, told the House of Commons on Tuesday.

Beginning in July, the company said they have the capacity to produce 50,000 vials per day, with each vial containing 10 doses.

“Our total capacity that we could produce in 2021 would be 50 million doses,” said Brad Sorenson, chief executive officer of Providence Therapeutics, during a virtual standing committee meeting.

The company said they are now receiving orders from provinces and more information on those orders will be disclosed in the coming days.